Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF) Sees Significant Decrease in Short Interest

Posted by Latisha Jones on Oct 16th, 2026

Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF – Get Free Report) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totaling 38,370 shares, a drop of 39.1% from the September 15th total of 63,055 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 1 shares, the short-interest ratio is presently 38,370.0 days.

Recordati Industria Chimica E Farmaceutica Price Performance

Recordati Industria Chimica E Farmaceutica stock remained flat at $58.79 during mid-day trading on Friday. The company has a current ratio of 1.26, a quick ratio of 0.86 and a debt-to-equity ratio of 0.79. The firm has a market cap of $12.13 billion, a price-to-earnings ratio of 20.97 and a beta of 0.26. Recordati Industria Chimica E Farmaceutica has a one year low of $55.88 and a one year high of $60.00. The business’s fifty day simple moving average is $58.17 and its two-hundred day simple moving average is $57.91.

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported $0.91 earnings per share (EPS) for the quarter. Recordati Industria Chimica E Farmaceutica had a return on equity of 33.73% and a net margin of 18.38%. The company had revenue of $810.70 million for the quarter.

Recordati Industria Chimica E Farmaceutica Company Profile

(Get Free Report)

Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its activities are centered on specialty-care and rare-disease treatments, with products addressing areas such as endocrinology, oncology, urology, cardiology, gastroenterology and other specialized medical needs.

The company markets both proprietary and licensed medicines, serving patients through prescription products and therapies for uncommon or underserved conditions.